Aquestive Therapeutics Inc. is a specialty pharmaceutical company that develops and commercializes orally administered therapies. Based in New Jersey, the company leverages its proprietary PharmFilm technology to create soluble film formulations that improve drug absorption and patient compliance, primarily targeting central nervous system disorders and severe allergic reactions. Its commercialized proprietary products include Sympazan for seizures associated with Lennox-Gastaut Syndrome and Exservan for amyotrophic lateral sclerosis (ALS). Aquestive also generates revenue through licensing and co-development agreements, notably manufacturing Suboxone sublingual film for opioid dependence. The company's late-stage clinical pipeline features Anaphylm, a sublingual epinephrine film for the emergency treatment of anaphylaxis, and Libervant, a buccal film for refractory epilepsy.
